Archives of neurology
-
Archives of neurology · Sep 2010
Randomized Controlled TrialA randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.
Interleukin 12 (IL-12), a cytokine that promotes generation of helper T cells subtype 1, is increased in multiple sclerosis. Albuterol sulfate, a β2-adrenergic agonist, reduces IL-12 expression, so we tested the effect of albuterol as an add-on treatment to glatiramer acetate therapy. ⋯ Treatment with glatiramer acetate plus albuterol is well tolerated and improves clinical outcomes in patients with multiple sclerosis.
-
Archives of neurology · Sep 2009
Randomized Controlled Trial Multicenter StudyDeterminants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
To assess the predictive value of baseline measures of impairment, disability, and quality of life for the timing of initiation of symptomatic treatment in early Parkinson disease (PD). ⋯ In early PD, greater impairment and disability and higher level of education are independently associated with an earlier need for symptomatic treatment.
-
Archives of neurology · May 2009
Randomized Controlled Trial Multicenter Study Comparative StudyLong-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
To compare the long-term outcomes of subjects initially treated with pramipexole dihydrochloride with those of subjects initially treated with levodopa in the Comparison of the Agonist Pramipexole With Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) trial. ⋯ The policies of initial pramipexole and initial levodopa use followed by open-label levodopa use resulted in similar self-reported disability 6 years after randomization. Persistent differences favoring initial pramipexole were seen in the rates of dopaminergic motor complications, with less severe somnolence favoring initial levodopa. Trial Registration clinicaltrials.gov Identifier: NCT00804479.
-
Archives of neurology · Aug 2008
Randomized Controlled Trial Multicenter Study Comparative StudyPhase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease. ⋯ LY450139 was generally well tolerated at doses of up to 140 mg/d for 14 weeks, with several findings indicating the need for close clinical monitoring in future studies. Decreases in plasma Abeta concentrations were consistent with inhibition of gamma-secretase. Trial Registration clinicaltrials.gov Identifier: NCT00244322.
-
Archives of neurology · Jul 2008
Randomized Controlled Trial Comparative StudyInternal pallidal and thalamic stimulation in patients with Tourette syndrome.
Tourette syndrome (TS) is thought to result from dysfunction of the associative-limbic territories of the basal ganglia, and patients with severe symptoms of TS respond poorly to medication. High-frequency stimulation has recently been applied to patients with TS in open studies using the centromedian-parafascicular complex (CM-Pf) of the thalamus, the internal globus pallidus (GPi), or the anterior limb of the internal capsule as the principal target. ⋯ High-frequency stimulation of the associative-limbic relay within the basal ganglia circuitry may be an effective treatment of patients with TS, thus heightening the hypothesis of a dysfunction in these structures in the pathophysiologic mechanism of the disorder.